Multiple Sclerosis Clinical Trials in Houston

View 18 new treatments for Multiple Sclerosis in Houston, TX, and other areas near me, such as League City, Pearland and Sugar Land. Every day, Power helps hundreds of Multiple Sclerosis patients connect with leading medical research.
View 18 trials in Houston
Filter (18)

Ocrelizumab for Multiple Sclerosis

Research Clinic, Houston + 1 more

This trial is testing if patients with early relapsing multiple sclerosis can stop taking Ocrelizumab after initial treatment without their disease getting worse. Ocrelizumab is a medication given through an IV that helps manage multiple sclerosis by reducing harmful immune cells. The study will monitor patients for new disease activity over several years.Show More
Recruiting
Phase 4
Est. 5 - 8 Weeks
Amit Bar-Or, M.D.
Study Chair

Intensive vs Escalation Therapy Approaches for Multiple Sclerosis

Research Clinic, Houston + 2 more

The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Nikos Evangelou, MD, DPhil
Principal Investigator

Ofatumumab for Early Relapsing-Remitting Multiple Sclerosis

Novartis Clinic, Houston + 2 more

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes. The study will also assess changes in disease using monitoring techniques including digital biometric device use, biomarker analysis and non-conventional MRI. Select outcomes in the ofatumumab treated group will be compared to a group of Healthy participants to determine if there are similarities between the groups after the patients with MS undergo treatment with ofatumumab.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Ofatumumab for Multiple Sclerosis

Novartis Clinic, Webster + 4 more

This trial will test if patients with a specific type of multiple sclerosis benefit from switching to a new medication. The medication aims to reduce harmful cells in the nervous system, potentially preventing future issues. It has been approved in several countries for treating this condition.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

High-Dose Ocrelizumab for Multiple Sclerosis

Hoffmann-La Roche Clinic, Houston + 1 more

This trial is testing if a higher dose of ocrelizumab given through an IV drip is more effective and safe for patients with Primary Progressive Multiple Sclerosis (PPMS). The drug works by reducing harmful immune cells to potentially slow down the disease. Ocrelizumab is the first drug approved for treating both relapsing and primary progressive forms of multiple sclerosis.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Clinical Trials
Study Director

Ofatumumab for Multiple Sclerosis

Novartis Clinic, Houston + 2 more

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Ocrelizumab vs Fingolimod for Pediatric Multiple Sclerosis

Hoffmann-La Roche Clinic, Houston + 1 more

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and \< 18 years over a flexible duration. The double-blind period will last until after the last participant randomized has completed 24 weeks.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Clinical Trials
Study Director

Tolebrutinib for Primary Progressive Multiple Sclerosis

Sanofi Clinic, Katy + 3 more

Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relationship to efficacy and safety To evaluate pharmacodynamics of SAR442168Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Clinical Sciences & Operations
Study Director

Remibrutinib vs Teriflunomide for Multiple Sclerosis

Novartis Clinic, Houston + 2 more

This trial compares two medications, remibrutinib and teriflunomide, for treating patients with relapsing multiple sclerosis. These patients have repeated episodes of symptoms and need effective treatments. The medications work by controlling the immune system to prevent it from causing damage to the nervous system. Teriflunomide is an approved medication for adults with relapsing multiple sclerosis.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Novartis Pharmaceuticals
Study Director

Stem Cell Transplant vs Best Available Therapy for Multiple Sclerosis

Research Clinic, Houston + 1 more

This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Paolo A. Muraro, MD, PhD
Study Chair
Page 1 of 2

Frequently Asked Questions

How much do multiple sclerosis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do multiple sclerosis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across multiple sclerosis trials in Houston, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for multiple sclerosis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Houston is research being conducted for multiple sclerosis?

Prominent locations in Houston conducting multiple sclerosis clinical trials include Baylor College of Medicine. Trials are concentrated in the southern part of the city, with approximately 6 ongoing as of 2024.

What promising new drugs are being tested?

In Houston, research for multiple sclerosis includes treatments like Monoclonal Antibodies and Immunomodulators. Notable drugs being studied are Ofatumumab, Ocrelizumab, and Teriflunomide.